Abpro Unveils Preclinical Data at Prominent Cancer Meet
Abpro Holdings, Inc. (NASDAQ: ABP), a pioneering biotechnology firm, is at the forefront of developing innovative antibody therapies aimed at treating severe and life-threatening diseases. Recently, the company announced an opportunity to present its preclinical findings on ABP-102/CT-P72, a cutting-edge bispecific T-cell engager focused on targeting HER2 x CD3, at a prestigious annual meeting hosted by the American Association for Cancer Research.
Details of the Presentation
The oral presentation is scheduled for the New Drugs on the Horizon session, set to take place on April 27. Adam J. Pelzek, Ph.D., the Associate Director at Abpro, will lead this significant discussion, which aims to shed light on ABP-102/CT-P72’s targeted capabilities against tumors that overexpress HER2. This bispecific T-cell engager represents a promising advancement in cancer immunotherapy.
Understanding ABP-102/CT-P72
ABP-102/CT-P72 has been meticulously designed with Abpro’s proprietary DiversImmune platform, enabling it to selectively bind to HER2-overexpressing tumor cells while minimizing its effects on normal tissues with lower HER2 expression levels. Its tetravalent IgG1-[L]-scFv structure facilitates strong binding to HER2, thereby optimizing its efficacy while reducing the risk of cytokine-related toxicities.
Strategic Collaboration with Celltrion
To further its development, Abpro has formed an exclusive partnership with Celltrion, a leading biotechnology company based in South Korea. This collaboration aims to expedite ABP-102/CT-P72’s development for treating various HER2-positive cancers, including those affecting the breast, gastric, pancreatic, and colorectal regions.
Abpro's Mission and Future Outlook
At the core of Abpro's values lies a commitment to enhance human life through next-generation antibody therapies. The company is not only focused on HER2-positive cancers but is also advancing treatments for gastric and liver cancers not driven by HER2, as well as addressing ocular diseases such as wet age-related macular degeneration and diabetic macular edema.
Abpro's antibody therapies are grounded in the innovative DiversImmune platform, which allows for the development of highly specialized immune responses tailored for various diseases. With operations based in Woburn, Massachusetts, Abpro continues to push the boundaries of therapeutic possibilities.
Frequently Asked Questions
What is ABP-102/CT-P72?
ABP-102/CT-P72 is a bispecific T-cell engager specifically designed to target HER2-overexpressing tumors and minimize effects on normal tissues with lower HER2 levels.
When will the presentation take place?
The oral presentation is scheduled for April 27.
Who is presenting at the AACR meeting?
Adam J. Pelzek, Ph.D., Associate Director at Abpro, will present the findings.
What is the significance of the collaboration with Celltrion?
The collaboration with Celltrion enhances Abpro's ability to advance ABP-102/CT-P72 for treating various cancers effectively.
How does Abpro contribute to next-generation therapies?
Abpro focuses on developing antibody therapies using its proprietary platform to address severe and life-threatening conditions.
